CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma
• * Recurrent disease following prior initial therapy with platinum-based regimen
• * No more than 2 prior cytotoxic chemotherapy regimens for recurrent disease
• * No more than 1 prior non-platinum, non-taxane regimen
• At least 1 site of radiographically measurable disease AND/OR
• CA-125 levels at least 50% above upper limits of normal for a minimum of 2 samples
• PATIENT CHARACTERISTICS:
• Age
• Not specified
• Performance status
• Karnofsky 70-100%
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• Bilirubin less than 1.5 times upper limit of normal (ULN)
• SGOT less than 1.5 times ULN
• Alkaline phosphatase less than 1.5 times ULN
• Renal
• Creatinine no greater than 1.5 mg/dL
• Other
• No unresolved, pre-existing grade 2 or greater neurotoxicity from prior treatment with neurotoxic drugs
• No active uncontrolled infection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 4 weeks after study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 4 weeks since prior immunotherapy and recovered
• Chemotherapy
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy and recovered
• Endocrine therapy
• At least 4 weeks since prior endocrine therapy and recovered
• Radiotherapy
• At least 4 weeks since prior radiotherapy (except for palliative reasons) and recovered
• Surgery
• Not specified
• Other
• At least 4 weeks since other prior investigational drugs and recovered